Drug Profile
AZD 2551
Alternative Names: AZD2551Latest Information Update: 12 Aug 2010
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antiasthmatics; Small molecules
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 29 Jul 2010 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
- 19 Mar 2009 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)
- 02 Feb 2006 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)